Mighty Pharma

Mighty Biopharma is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative biologics for autoimmune and inflammatory diseases. The company utilizes its proprietary Mighty-Mab antibody discovery and optimization platform to target clinically validated pathways with high-potential therapeutic candidates. Its lead program, MA022, is a monoclonal antibody targeting the IL-4Rα receptor, currently in Phase 2 clinical trials for atopic dermatitis and asthma. Other pipeline assets include antibodies targeting IL-17A, IL-5, and TSLP, aimed at addressing significant unmet needs in respiratory and dermatological conditions. Mighty Biopharma is backed by prominent venture capital firms and focuses on delivering high-quality, accessible treatments for patients worldwide.